Compare Gilead Sciences, Inc. (GILD) vs LyondellBasell Industries NV (LYB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs LyondellBasell Industries NV — how do they compare? Gilead Sciences, Inc. trades at $133.12 (market cap $163.51B), while LyondellBasell Industries NV trades at $58.62 (market cap $18.72B). The key difference: Gilead Sciences, Inc. is far larger — about 8.7× LyondellBasell Industries NV's market cap, and LyondellBasell Industries NV pays the higher dividend (7.1%). Which is the better fit depends on your goals.
| GILD | LYB | |
|---|---|---|
Market Cap | $163.51B | $18.72B |
Sector | Health | Basic Materials |
52-Week High | $155.80 | $82.38 |
52-Week Low | $108.22 | $42.28 |
Enterprise Value | $178.05B | $30.34B |
Dividend Yield | 2.49% | 7.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
LyondellBasell (LYB) trades at $58.56, up 0.4% on the day, with a bullish technical signal from moving averages. The company reported mixed quarterly earnings, beating estimates in Q3 2025 and Q1 2026 but missing in Q4 2025. Recent news highlights strategic partnerships for sustainable packaging, including a collaboration with Mondelez announced in July 2026. However, fundamental challenges persist with a net loss of $745 million in 2025 and negative profit margins.
The outlook presents a dichotomy: analyst consensus is a 'Buy' with a $73.11 price target, and recent Zacks upgrades to 'Strong Buy' in June 2026 reflect optimism on earnings prospects. Key opportunities include cost-cutting initiatives and a pivot to higher-margin polymers. Primary risks are sustained revenue decline, elevated debt, and cyclical industry pressures that could delay a profitability turnaround.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About LyondellBasell Industries NV
LyondellBasell Industries NV is a petrochemical producer with operations in the U.S. and Europe. It operates in six segments: Olefins and Polyolefins-Americas (O&P-Americas), Olefins and Polyolefins-Europe, Asia, International (O&P-EAI), Intermediates and Derivatives (I&D), Advanced Polymer Solutions (APS), Refining and Technology. The company is a major producer of polyethylene, the world's largest producer of polypropylene, and the second- largest producer of propylene oxide. Its chemicals are used in various consumer and industrial end products. Substantially, all of the company's revenue is derived from product sales.
Read more on LYB →
